Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
Movement Disorders with Cerebral Toxoplasmosis and AIDS
Movement Disorders 8:107-112, Nath,A.,et al, 1993
Subcortical Dementia
BMJ 307:1-2, Dunne,F.J., 1993
Extrapyramidal side Effects of Antiemetics Presenting as Psychiatric Illness
Gen Hosp Psychiatry 14:192-195, Rodgers,C., 1992
Practice Parameter: Treatment of Nonmotor Symptoms of Parkinson Disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:924-931, Zesiewicz,T.A.,et al, 2010
Clinical Usefulness of Magnetic Resonance Imaging in Multiple System Atrophy
JNNP 65:65-71, Schrag,A.,et al, 1998
Clinicopathological Study of 35 Cases of Multiple System Atrophy
JNNP 58:160-166, Wenning,G.K.,et al, 1995
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Presynaptic Parkinsonism in Olivopontocerebellar Atrophy:Clinical, pathological, and Neurochemical Evidence
Ann Neurol 30:425-428, Pascual,J.,et al, 1991
Transplantation in Parkinson's Disease:Two Cases of Adrenal Medullary Grafts to the Putamen
Ann Neurol 22:457-468, Lindvall,O.,et al, 1987
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Viral Hepatitis and Parkinson Disease
Neurol 88:1630-1633, Pakpoor, J.,et al, 2017
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of DIagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality
AJNR 36:2010-2016, Noh, Y.,et al, 2015
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
A Randomized, Double-Blind, Placebo-Controlled Trial of Antidepressants in Parkinson Disease
Neurol 78:1229-1236, Richard,I.H.,et al, 2012
Effects of a Central Cholinesterase Inhibitor on Reducing Falls in Parkinson Disease
Neurol 75:1263-1269, Chung,K.A.,et al, 2010
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Alzheimer's Disease and Parkinson's Disease
NEJM 348:1356-1364, Nussbaum,R.L. &Ellis,C.E., 2003
Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
Impact of Sustained Deprenyl (Selegiline) in Levodopa-Treated Parkinson's Disease: A Randomized Placebo-Controlled Extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial
Ann Nuerol 51:604-612, Shoulson,I.,et al, 2002
Intakes of Vitamins E and C, Carotenoids, Vitamin Supplements, and PD Risk
Neurol 59:1161-1169, Zhang,S.M.,et al, 2002
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
Complete Genomic Screen in Parkinson Disease
JAMA 286:2239-2244, Scott,W.K.,et al, 2001
Depression in Parkinson's Disease
BMJ 320:1287-1288, Allain,H.,et al, 2000
The Catechol-O-Methyltransferase (COMT) Inhibitor Entacapone Enhances the Pharmacokinetic and Clinical Response to Sinemet CR in Parkinson's Disease
JNNP 68:589-594, Piccinni,P.,et al, 2000
Selegiiline and Mortality in Subjects with Parkinson's Disease
Neurol 55:1785-1789,1770, Donnan,P.T.,et al, 2000
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998